Doxorubicin·Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo<i> </i>

• Main Authors: Sun Jung Yoon, Young Jae Moon, Heung Jae Chun, Dae Hyeok Yang
• Format: Article
• Language: English
• Published: MDPI AG 2019-11-01
• Series: Nanomaterials
• Subjects: osteosarcoma; visible light-cured glycol chitosan hydrogel; (2-hydroxypropyl)-beta-cyclodextrin; doxorubicin·hydrochloride; cisplatin; local drug delivery system; cardiotoxicity; nephrotoxicity
• Online Access: https://www.mdpi.com/2079-4991/9/12/1652

Osteosarcoma (OSA) is a difficult cancer to treat due to its tendency for relapse and metastasis; advanced methods are therefore required for OSA treatment. In this study, we prepared a local drug-delivery system for OSA treatment based on doxorubicin&#183;hydrochloride (DOX&#183;HCl)/cisplatin (CP)-loaded visible light-cured glycol chitosan (GC) hydrogel/(2-hydroxypropyl)-beta-cyclodextrin (GDHCP), and compared its therapeutic efficiency with that of DOX&#183;HCl- and CP-loaded GC hydrogels (GD and GHCP). Because of diffusion driven by concentration gradients in the swollen matrix, the three hydrogels showed sustained releases of DOX&#183;HCl and CP over 7 days, along with initial 3-h bursts. Results of in vitro cell viability and in vivo animal testing revealed that GDHCP had a stronger anticancer effect than GD and GHCP even though there were no significant differences. Body weight measurement and histological evaluations demonstrated that the drug-loaded GC hydrogels had biocompatibility without cardiotoxicity or nephrotoxicity. These results suggested that GDHCP could be a good platform as a local drug-delivery system for clinical use in OSA treatment.